PLX3397

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hodgkin Lymphoma

Conditions

Hodgkin Lymphoma

Trial Timeline

Mar 3, 2011 → Apr 26, 2012

NCT ID

NCT01217229

About PLX3397

PLX3397 is a phase 2 stage product being developed by Daiichi Sankyo for Hodgkin Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01217229. Target conditions include Hodgkin Lymphoma.

What happened to similar drugs?

9 of 20 similar drugs in Hodgkin Lymphoma were approved

Approved (9) Terminated (2) Active (9)

✅Chemotherapy + Immunochemotherapy + PegfilgrastimRocheApproved

✅rituximab [MabThera/Rituxan]RocheApproved

✅TenofovirGilead SciencesApproved

✅temsirolimus + temsirolimusPfizerApproved

✅Kepivance (Palifermin)Swedish Orphan BiovitrumApproved

✅Entecavir prophylaxis + Therapeutic entecavirBristol Myers SquibbApproved

✅Granulocyte-colony stimulating factor (G-CSF) + Fixed Dose Plerixafor + Weight-Based PlerixaforSanofiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02975700	Pre-clinical	Completed	Jan 31, 2017	Oct 11, 2024	Melanoma
NCT01499043	Phase 2	Terminated	May 25, 2012	Mar 11, 2013	Prostate Cancer
NCT01349036	Phase 2	Terminated	Dec 3, 2011	Nov 5, 2013	Recurrent Glioblastoma
NCT01217229	Phase 2	Completed	Mar 3, 2011	Apr 26, 2012	Hodgkin Lymphoma
NCT01004861	Phase 1	Completed	Oct 1, 2009	Oct 25, 2018	Solid Tumor

Competing Products

20 competing products in Hodgkin Lymphoma

See all competitors

Product	Company	Stage	Hype Score
AFM13	Affimed	Phase 2	25
VIP152 + BTKi	Vincerx Pharma	Phase 1	11
YM155 + Rituximab	Astellas Pharma	Phase 2	35
Tazemetostat	Eisai	Phase 2	35
ONTAK	Eisai	Phase 2	35
Tazemetostat	Eisai	Phase 1	29
ME-401	Kyowa Kirin	Phase 1	29
ME-401	Kyowa Kirin	Phase 2	39
Tirabrutinib	Ono Pharmaceutical	Phase 1	29
ONO-7018	Ono Pharmaceutical	Phase 1	33
Nivolumab + Brentuximab vedotin	Ono Pharmaceutical	Phase 3	32
ONO-7018 + ONO-7018	Ono Pharmaceutical	Phase 1	33
R-mabHDI and ABVD + ABVD	Eli Lilly	Phase 3	36
Prednisone + Vinblastine + Doxorubicin (Adriamycin) + Gemcitabine	Eli Lilly	Phase 1/2	32
gemcitabine	Eli Lilly	Phase 2	27
gemcitabine + cisplatin + dexamethasone	Eli Lilly	Phase 2	35
LY4152199 - IV	Eli Lilly	Phase 1	36
R-mabHD + ABVD	Eli Lilly	Phase 2	31
enzastaurin + placebo	Eli Lilly	Phase 3	40
LY317615	Eli Lilly	Phase 2	35